Abstract
As part of a new program, China’s central government and three drug manufacturers have agreed on major reductions in the price of three patented drugs. The agreement may provide a blueprint for resolving the conflicting interests of patients seeking access to essential drugs and major drug companies trying to earn a profit in China. GlaxoSmithKline, which is trying to rebuild its reputation in China after a 2014 bribery scandal, will reduce by two thirds the price of Viread, an antiretroviral that treats hepatitis B and HIV. Hepatitis B afflicts more than 7% of China’s population, and some 28 million people in the country are said to be in need of antiviral treatment. AstraZeneca will cut by more than half the price of its breast and lung cancer drug Iressa. And the Chinese firm Beta Pharma will also more than halve the price of its lung cancer drug Conmana, which was
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
